Do you want to read an article? Please log in or register.
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung, Respiratory and Thoracic Cancer
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
J Thorac Oncol
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS
doi: 10.1016/j.jtho.2025.05.019
Lung, Respiratory and Thoracic Cancer
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
N Engl J Med
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N, CheckMate 816 Investigators
doi: 10.1056/NEJMoa2502931
Lung, Respiratory and Thoracic Cancer
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
Ann Oncol
Wang C, Wang W, Liu H, Chen Q, Chen C, Liu L, Zhang P, Zhao G, Yang F, Han G, Yu B, Yang Y, Chen H, Jiang J, Tan L, Xu S, Mao N, Hu J, Zhang L, Zhang Z, Yao B, Wang S, Leaw S, Naicker K, Zheng W, Yu C, Yue D, RATIONALE-315 investigators
doi: 10.1016/j.annonc.2025.11.017
Lung, Respiratory and Thoracic Cancer
Surgical results after neoadjuvant nivolumab and platinum-based chemotherapy for resectable lung cancer. A multicentre European real clinical practice analysis
Eur J Cardiothorac Surg
Brunelli A, Mariolo A, Aigner C, De Antonio DG, Jimenez M, Hemead H, Hoffman R, Lodhia J, Nardini M, Mattioni G, Sinn K, Hoda MA, Novoa N, Davila GR, Gomez-Hernandez MT, Rivas-Duarte C, Bhatnagar P, Clarke K, Escriu C, Fakih O, Franks K, Bouaziz K, Calvo V, Sereno M, Provencio M, Girard N, Shackcloth M
doi: 10.1093/ejcts/ezaf343
Lung, Respiratory and Thoracic Cancer
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
J Thorac Oncol
Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC
doi: 10.1016/j.jtho.2026.103609
Lung, Respiratory and Thoracic Cancer
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers
Lung Cancer
Agrawal P, Rotow J, Rocco G, Travis W, Ortiz E, Scalabrino R, LoPiccolo J, Facchinetti F, Kris MG, Yu HA, Jones D, Chaft JE
doi: 10.1016/j.lungcan.2025.108795
Lung, Respiratory and Thoracic Cancer
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
Lung Cancer
Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, Çİl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC
doi: 10.1016/j.lungcan.2026.109302
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548